Royalty Pharma (RPRX) Free Cash Flow (2019 - 2026)
Royalty Pharma (RPRX) posted Free Cash Flow of $265.9 million for Q1 2026, up 184.46% sequentially from $93.5 million in Q4 2025, and down 55.32% YoY from $595.0 million in Q1 2025.
Royalty Pharma (RPRX) Free Cash Flow (2019 - 2026) Analysis & Trends
Royalty Pharma has reported Free Cash Flow for 8 years, with the latest figure at $265.9 million in Q1 2026.
- Quarterly Free Cash Flow fell 55.32% year-over-year to $265.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $462.9 million (up 65.48% YoY) and the FY2025 annual result came in at $792.1 million, up 200.85% from the prior year.
- Free Cash Flow rose to $265.9 million in Q1 2026 per RPRX's latest filing, from $93.5 million in the prior quarter.
- Over five years, Free Cash Flow peaked at $595.0 million in Q1 2025 and troughed at -$777.5 million in Q3 2022.
- A 5-year average of $152.7 million and a median of $265.9 million in 2026 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2022 and 2024: Free Cash Flow soared 1898.2% in 2022, then sank 501.15% in 2024.
- Over 5 years, Free Cash Flow stood at $319.7 million in 2022, then tumbled by 171.82% to -$229.6 million in 2023, then surged by 207.18% to $246.1 million in 2024, then sank by 62.02% to $93.5 million in 2025, then surged by 184.46% to $265.9 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered $265.9 million, $93.5 million, and -$259.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -268.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 477.44 Mn |
| Jun 30, 2026 | 477.44 Mn |
| Mar 31, 2026 | 265.87 Mn |
| Mar 31, 2026 | 265.87 Mn |
| Dec 31, 2025 | 93.46 Mn |
| Dec 31, 2025 | 93.46 Mn |
| Sep 30, 2025 | -259.26 Mn |
| Sep 30, 2025 | -259.26 Mn |
| Jun 30, 2025 | 362.87 Mn |
| Jun 30, 2025 | 362.87 Mn |
| Mar 31, 2025 | 595.02 Mn |
| Mar 31, 2025 | 595.02 Mn |
| Dec 31, 2024 | 246.11 Mn |
| Dec 31, 2024 | 246.11 Mn |
| Sep 30, 2024 | -490.96 Mn |
| Sep 30, 2024 | -490.96 Mn |
| Jun 30, 2024 | -70.42 Mn |
| Jun 30, 2024 | -70.42 Mn |
| Mar 31, 2024 | 578.55 Mn |
| Mar 31, 2024 | 578.55 Mn |